Show simple item record

dc.contributor.authorConstantinidou, Anastasiaen
dc.contributor.authorJones, Robin Lewisen
dc.contributor.authorReis-Filho, J. S.en
dc.contributor.editorHudis, Clifford A.en
dc.contributor.editorTraina, Tiffany A.en
dc.creatorConstantinidou, Anastasiaen
dc.creatorJones, Robin Lewisen
dc.creatorReis-Filho, J. S.en
dc.description.abstractTriple-negative breast cancers comprise a heterogeneous group of tumors with varying prognosis, but the majority are of high histological grade and have a poor prognosis. Although there is considerable overlap between triple-negative and basal-like breast cancers, the two are not synonymous. Triple-negative breast cancers also encompass other microarray-defined molecular subtypes, such as the molecular apocrine and claudin-low subtypes. Other subtypes may emerge through more detailed microarray-based and massively parallel sequencing analyses. The term triple-negative breast cancer is merely operational and is likely to be replaced by a predictive terminology, which will lead to a better utilization of available therapies and the introduction of targeted therapeutic agents for the management of patients with triple-negative disease. © 2011 Future Medicine Ltd. All rights reserved.en
dc.publisherFuture Medicine Ltd.en
dc.titleMolecular subtypes and emerging therapeutic opportunitiesen
dc.description.endingpage36Ιατρική Σχολή / Medical SchoolΙατρική Σχολή / Medical School
dc.type.uhtypeBook Chapteren
dc.contributor.orcidConstantinidou, Anastasia [0000-0001-5316-7574]

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record